Answers from the Lab

(00:31)
 Could you each provide us a little bit about yourself and your background? Dr. Zheng, we'll start with you.

(01:40)
 Dr. Mansfield, how about you?

(02:07) 
 Could you explain a little bit about the new biopsy test and the technology?

(03:58)
 Which patients should have this testing and when should it be used?

(06:44)
 What alternative test options are available and how would they compare to the Mayo complete cell-free DNA panel?

(08:28)
 Can you go into a little more detail from a clinical practice perspective about how these tests are used?

(10:16)
 Dr. Zheng, is there anything else you would like to add to this discussion?

(10:53)
 Dr. Mansfield, is there anything else you would like to add to this discussion?

(01:11)

Dr. Hasadsri, could you provide us with an overview of what carrier screening is?

(02:28)
Can you really expand on why these tests are important?

(05:25)
So in your experience, who could benefit from carrier screening and when should that testing be performed?

(06:45)
Can you just share how does a healthcare provider order carrier screening and then secondarily what sample types are accepted?

(08:05)
Can you share what are some of the unique features of our testing that sets the Mayo Clinic Laboratories apart?

(10:36)
So the last question I have is could you just summarize the benefits of doing carrier screening at Mayo?

(00:32)
 Can you tell us a little bit about yourself, your background and your role at Mayo Clinic?

(01:08)
 How long have you been with Mayo Clinic and where were you previously?

(01:37) 
 Can you tell us a little bit about the panel and explain why these four tests were chosen over other combinations of tests?

(07:43)
 Which patients would this panel be used for and when should the panel be run?

(09:26)
 Is there anything else you'd like to explain about this panel?

(00:31)
 Can you please provide us a little bit of background about yourself?

(01:29)
 Can you give us an overview of this assay?

(02:44)
 Can you talk about what genes have been added, and why?

(04:16)
 Can you talk about patients who should have this testing?

(06:20)
 Are there any last comments that you would like to make about the new gastrointestinal tumor panel?

(00:32)
 Could you provide a little bit of background about yourself?

(01:43)
 Could you give a brief overview of the new melanoma assay?

(04:53)
 Is the assay able to provide diagnostic, prognostic and classification information, and potential therapeutic implications?

(05:12)
 Could you talk a little more about the MSI assessment in this panel? 

(05:59)
 Which patients should have this testing?

(07:01)
 How are these results used in patient care?

(08:39)
 Is there anything else you'd like to add?